North America and Europe PEGylated Drugs Market to hit $10.5 bn by 2024

Sellbyville, DE -- (SBWire) -- 04/29/2019 --The North America and Europe PEGylated Drugs Market to exceed USD 10.5 billion by 2024; according to a new research report by Global Market Insights. Growing biologics sector such as, new advances in cell therapies, immunotherapies, antibody drug conjugates, gene therapies will offer immense growth opportunities in the future. Increasing acceptance of biologics drugs such as, monoclonal antibodies, colony stimulating factors, and interferons for treatment of chronic diseases will upsurge revenue share of PEGylated drugs in developed regions. However, drug recalls and adverse drug reactions associated with pegylated drugs will hinder North America and Europe PEGylated Drugs Market growth during the forecast timeframe.

Rising prevalence of chronic diseases including cancer in developed regions coupled with increasing R&D spending by pharmaceutical and biotechnology companies will drive the PEGylated drugs market size. As per American Cancer Society, over 15.5 million Americans are living with cancer and more than 1.7 million new cases are anticipated to be diagnosed in 2018. This will foster demand for North America and Europe PEGylated Drugs Market in the future.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511

Cancer segment held over 60% of the overall market share in 2017 due to growing prevalence of the disease creating a demand for the development of effective drugs. Benefits offered by PEGylated drugs such as reduced proteolytic degradation along with minimized immunogenicity leading to enhanced therapeutic efficacy will propel North America and Europe PEGylated Drugs Market growth. Increasing areas of applications as well as rising adoption of PEGylated drugs to treat various types of cancer will stimulate business growth.

Hepatitis segment size was USD 156 million in 2017 and is anticipated to follow a declining trend over the forecast period. However, increasing focus of industry players to develop pegylated drugs used for the treatment of such chronic conditions will contribute to market growth. For instance, launch of Pegasys drug used for treating Hepatitis C in adult patients will fuel market growth.

Concurrently, it has been observed that a number of prominent firms are focusing on development and commercialization of targeted therapies to treat rare illnesses. For instance, one of the notable participants in North America and Europe PEGylated drugs market, Eiger BioPharmaceuticals, Inc recently announced to have received orphan designation by U.S. FDA for its pegylated interferon lambda 1a. The Orphan Drug Designation Program provides orphan status to biologics and drugs which have been defined as safe for diagnosing, treating or preventing rare illnesses that affect less than 200,000 residents of the U.S.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Roche
- AstraZeneca
- Pfizer
- Amgen
- Biogen
- Novo Nordisk
- UCB
- Merck KGaA

As has been reported, the latest drug by Eiger is being termed as an effective potential treatment for chronic hepatitis delta virus (HDV) infection. Moreover, Lambda is said to be a first in class, well-characterized, late stage, type III interferon that stimulates immune responses which are considered critical for generating host protection from viral infections.

For the record, hepatitis delta is considered as one of the most severe forms of viral hepatitis in humans and is caused by infection with HDV. With a significant impact on global health, hepatitis delta, as per reliable estimates, affects about 15-20 million people worldwide. Therefore, the launch of Eiger's Lambda is anticipated to predominantly assist healthcare providers in lowering the mortality rates caused by hepatitis delta. This would eventually propel the commercialization potential of North America and Europe PEGylated drugs market over the ensuing years from hepatitis treatment application. The segment accounted for a revenue of USD 156 million in 2017.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511

U.S. PEGylated drugs market size was over USD 6 billion in 2017 and is expected to surpass USD 8 billion by 2024. Significant market growth can be attributed to growing incidences of cancer along with rising mortality rates associated with chronic ailments in the country. Additionally, U.S. attracts most of the worldwide project capital investments in start-up biopharmaceutical enterprises. Availability of approved pegylated drugs along with numerous drugs in pipeline will foster business growth. Moreover, rising usage of biologics along with various awareness drives planned by government upsurges PEGylated drugs revenue size.

Few notable industry players operating in North America and Europe PEGylated drugs market are Shire Group, UCB, Merck, AstraZeneca, Amgen, Sigma Tau, Biogen, Pfizer and Roche. Industry players attempt to develop enhanced and effective PEGylated drugs for treating chronic conditions. Robust pipeline and ongoing research studies coupled with high R&D investment in PEGylation technology is anticipated to propel industry growth.

Chapter 1. Methodology

1.1. Methodology

1.1.1. Methodology

1.1.2. Market definition

1.1.3. Forecast parameters

1.1.4. Data sources

1.1.4.1. Primary

1.1.4.2. Secondary

Chapter 2. Executive Summary

2.1. North America & Europe PEGylated drugs industry 3600 synopsis, 2013 - 2024 (USD Million)

2.1.1. Business trends

2.1.2. Disease indication trends

2.1.3. Type trends

2.1.4. Regional trends

Browse Full Report@ https://www.gminsights.com/industry-analysis/north-america-and-europe-pegylated-drugs-market

Chapter 3. North America & Europe PEGylated Drugs Industry Insights

3.1. Industry segmentation

3.2. Industry impact forces

3.2.1. Growth drivers

3.2.1.1. Increasing prevalence of cancer in developed regions

3.2.1.2. Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe

3.2.1.3. Growing biologics sector in the developed economies